Mersana Therapeutics Inc logo

Mersana Therapeutics Inc

FRA:0M4 (USA)  
€ 4.10 (+4.73%) Mar 27
At Loss
P/B:
13.95
Market Cap:
€ 503.95M ($ 545.38M)
Enterprise V:
€ 341.97M ($ 370.08M)
Volume:
-
Avg Vol (2M):
1.07K
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
1.07K

Business Description

Mersana Therapeutics Inc logo
Mersana Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US59045L1061
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Name Current Vs Industry Vs History
Cash-To-Debt 6.22
Equity-to-Asset 0.16
Debt-to-Equity 0.91
Debt-to-EBITDA -0.2
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.96
Distress
Grey
Safe
Beneish M-Score -2.99
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 38.34
9-Day RSI 40.73
14-Day RSI 46.59
6-1 Month Momentum % 244.85
12-1 Month Momentum % -7.68

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.36
Quick Ratio 3.36
Cash Ratio 3.29
Days Sales Outstanding 297.11

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -20.6
Shareholder Yield % -17.6

Financials (Next Earnings Date:2024-05-09 Est.)

FRA:0M4's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Mersana Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 34.147
EPS (TTM) (€) -1.395
Beta -0.92
Volatility % 143.17
14-Day RSI 46.59
14-Day ATR (€) 0.207766
20-Day SMA (€) 4.6897
12-1 Month Momentum % -7.68
52-Week Range (€) 0.8278 - 8.764
Shares Outstanding (Mil) 121.3

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mersana Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Mersana Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Mersana Therapeutics Inc Frequently Asked Questions

What is Mersana Therapeutics Inc(FRA:0M4)'s stock price today?
The current price of FRA:0M4 is €4.10. The 52 week high of FRA:0M4 is €8.76 and 52 week low is €0.83.
When is next earnings date of Mersana Therapeutics Inc(FRA:0M4)?
The next earnings date of Mersana Therapeutics Inc(FRA:0M4) is 2024-05-09 Est..
Does Mersana Therapeutics Inc(FRA:0M4) pay dividends? If so, how much?
Mersana Therapeutics Inc(FRA:0M4) does not pay dividend.

Press Release

Subject Date
No Press Release